Company intelligence / Profile preview

IPGDx

Harrisville, Michigan, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

IPGDx has developed proprietary medical technologies including the PrognostiCheck® device for objective prognosis measurement in oncology indications such as adenocarcinoma, mesothelioma, breast cancer, and lung cancer. The EFresh® device measures food freshness non-destructively. The CDM™ system enables personalized drug dosing based on specific biomarker values. These products are designed to help patients live better lives and assist healthcare professionals with improved decision-making.

Therapeutic areas: OncologyOther
Modalities: DeviceDiagnostic deviceDrug dose modification system (enabling technology)
Industry: Physiological Monitoring

Beyond the preview

Go deeper on IPGDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPGDx.

Explore the full profile